drugset / Trial / NCT01029158

A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo

NCT01029158

Phase 1 Completed 84 enrolled Renovo
RandomizedSingle-groupDouble-blindBasic science

Summary

RN1006 has been developed as a stabilized formulation of avotermin which, when dosed once in pre-clinical studies in animals, has shown comparable scar improvement efficacy to the standard twice-dosed Juvista formulation. The aim of this trial is to investigate the efficacy of RN1006 compared to Juvista in a human volunteer model

Timeline

Start
2009-08
Primary completion
2010-09
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Avotermin Protein / enzyme biologic 205 ng Other
Subject Avotermin Protein / enzyme biologic 250 ng Other
Subject Avotermin Protein / enzyme biologic 500 ng Other

Indications

No indication recorded.